Paxman: CIPN-data continues to look excellent - Redeye
Redeye is positive about the updated data from Paxman’s CIPN clinical trial in Singapore. We argue that the data continues to be great and that the PLCS system could become a highly valuable tool within cancer care.
ANNONS
Redeye is positive about the updated data from Paxman’s CIPN clinical trial in Singapore. We argue that the data continues to be great and that the PLCS system could become a highly valuable tool within cancer care.
